Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and IBM

Premium

Affymetrix and IBM have launched a collaboration designed to help clinicians integrate genomic data with patient data such as medical histories and lab tests, Affymetrix said Tuesday.

The Santa Clara, Calif.-based maker of the GeneChip microarray product line will work with IBM professional services so that data derived from analysis conducted on the company’s proprietary hardware and software platforms can be referenced with medically relevant data as well as used in regulatory compliance efforts.

The announcement brings a prestigious information technology partner, IBM, together with Affymetrix, the leader of the pre-printed microarray market, and focuses on a potentially lucrative area in data management and the challenging process of integrating disparate data seamlessly.

Affymetrix said it plans to work, in collaboration with IBM, to promote open standards and new protocols for cross organizational and cross-disciplinary integration of patient data with genomic and molecular research data.

— MOK

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.